3750 — Cytori Cell Research Institute Income Statement
0.000.00%
Last trade - 00:00
- ¥8bn
- ¥15bn
- ¥2bn
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,925 | 1,180 | 1,388 | 1,336 | 2,145 |
Cost of Revenue | |||||
Gross Profit | 489 | 756 | 760 | 859 | 1,269 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,601 | 802 | 1,975 | 1,531 | 3,147 |
Operating Profit | 323 | 378 | -587 | -195 | -1,002 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 594 | 319 | -654 | -65.3 | -1,166 |
Provision for Income Taxes | |||||
Net Income After Taxes | 593 | 317 | -775 | -77.1 | -1,060 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 593 | 319 | -832 | -77.6 | -1,060 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 593 | 319 | -832 | -77.6 | -1,060 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 30.4 | 2.22 | -108 | -23.3 | -98.4 |
Dividends per Share |